Literature DB >> 12615426

Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.

Jay S Dela Cruz1, Suk Ying Lau, Ernesto M Ramirez, Carla De Giovanni, Guido Forni, Sherie L Morrison, Manuel L Penichet.   

Abstract

Previously protein vaccines consisting of the extracellular domain of HER2/neu (ECD(HER2)) were shown to elicit an immune response that does not provide protection against transplantable tumors expressing HER2/neu. Here, we showed that when mice were vaccinated with a mixture of human ECD(HER2) and anti-human HER2/neu IL-12, IL-2 or GM-CSF fusion proteins, significant retardation of the growth of a syngeneic carcinoma expressing rat HER2/neu, and long-term survivors were observed. Immune sera inhibited the in vitro growth of SK-BR-3, a human breast cancer overexpressing HER2/neu. Transfer of immune sera into mice challenged with TUBO also led to partial inhibition of tumor growth. Splenocytes from mice vaccinated with ECD(HER2) plus IgG3-(GM-CSF) incubated with ECD(HER2) demonstrated significant proliferation and IFN-gamma secretion. Taken together these results suggest that vaccines including ECD(HER2) and Ab-cytokine fusion proteins may be used to elicit both humoral and cell-mediated responses against HER2/neu.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615426     DOI: 10.1016/s0264-410x(02)00741-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.

Authors:  Tracy R Daniels; Richard K Leuchter; Rafaela Quintero; Gustavo Helguera; José A Rodríguez; Otoniel Martínez-Maza; Birgit C Schultes; Christopher F Nicodemus; Manuel L Penichet
Journal:  Cancer Immunol Immunother       Date:  2011-11-30       Impact factor: 6.968

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

3.  Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein.

Authors:  Rosendo Luria-Pérez; Pierre V Candelaria; Tracy R Daniels-Wells; José A Rodríguez; Gustavo Helguera; Manuel L Penichet
Journal:  Cytokine       Date:  2019-05-20       Impact factor: 3.861

4.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 5.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

6.  Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.

Authors:  Hui Ding; Gustavo Helguera; José A Rodríguez; Janet Markman; Rosendo Luria-Pérez; Pallavi Gangalum; Jose Portilla-Arias; Satoshi Inoue; Tracy R Daniels-Wells; Keith Black; Eggehard Holler; Manuel L Penichet; Julia Y Ljubimova
Journal:  J Control Release       Date:  2013-06-12       Impact factor: 9.776

7.  Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.

Authors:  Sepideh Afshar; Tsuneaki Asai; Sherie L Morrison
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

8.  Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.

Authors:  Johanna K Morales; Maciej Kmieciak; Laura Graham; Marta Feldmesser; Harry D Bear; Masoud H Manjili
Journal:  Cancer Immunol Immunother       Date:  2008-11-01       Impact factor: 6.968

9.  Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.

Authors:  Andrea M Henle; Courtney L Erskine; Linda M Benson; Raphael Clynes; Keith L Knutson
Journal:  J Immunol       Date:  2012-11-23       Impact factor: 5.422

10.  The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.

Authors:  Alexios Dimitriadis; Chrysanthi Gontinou; Constantin N Baxevanis; Avgi Mamalaki
Journal:  BMC Cancer       Date:  2009-10-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.